Table 2.
Antimicrobial susceptibility profiles for 12 clinical isolates of Kroppenstedtia eburneaa
| Isolate | MIC (μg/ml) |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T/S | CIP | MXF | AMI | DOX | TGC | CLA | LZD | IMI | FEP | AUG | AXO | MIN | TOB | |
| B | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 4 | ≤2/1 | ≤4 | ≤1 | ≤1 |
| C | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 4 | 4/2 | ≤4 | ≤1 | ≤1 |
| D | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 4 | ≤2/1 | ≤4 | ≤1 | ≤1 |
| E | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | 4/2 | ≤4 | ≤1 | ≤1 |
| F | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | 8/4 | 8 | ≤1 | ≤1 |
| G | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | ≤2/1 | ≤4 | ≤1 | ≤1 |
| H | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 4 | ≤2/1 | ≤4 | ≤1 | ≤1 |
| I | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | 4/2 | ≤4 | ≤1 | ≤1 |
| J | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | 4/2 | ≤4 | ≤1 | ≤1 |
| L | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | 4/2 | ≤4 | ≤1 | ≤1 |
| M | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | 0.06 | ≥32 | ≤1 | ≤2 | 8 | 4/2 | ≤4 | ≤1 | ≤1 |
| N | ≤0.25/4.8 | ≤0.12 | ≤0.25 | ≤1 | ≤0.12 | ≤0.015 | ≥32 | ≤1 | ≤2 | 8 | ≤2/1 | ≤4 | ≤1 | ≤1 |
a
Abbreviations: T/S, trimethoprim-sulfamethoxazole; CLA, clarithromycin; AXO, ceftriaxone; CIP, ciprofloxacin; LZD, linezolid; MIN, minocycline; MXF, moxifloxacin; IMI, imipenem; TOB, tobramycin; AMI, amikacin; DOX, doxycycline; FEP, cefepime; TGC, tigecycline; AUG, amoxicillin-clavulanic acid.